文献速递肝病

GT1型丙肝经索磷布韦联合NS5A抑制剂失败后G/P再治疗的耐药连锁分析

Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
PubMed 文献 · J Hepatol · 2021-05-21

本研究分析177例既往索磷布韦联合NS5A抑制剂治疗失败的HCV GT1患者,采用G/P再治疗。GT1b全部获得SVR12;GT1a基线NS5A耐药普遍,NS5A耐药连锁数量增加与SVR12率下降呈趋势,但无特定耐药位点或连锁模式显著降低SVR12。

要点

  • GT1b患者经G/P再治疗均获得SVR12,GT1a基线NS5A耐药常见但NS3耐药少见。
  • GT1a中基线NS5A耐药者SVR12数值低于无耐药者(89% vs 97%),无统计学差异。
  • NS5A耐药连锁数增加与SVR12率下降呈趋势,但无特定耐药位点或模式显著相关。

核心结论

  • G/P再治疗既往索磷布韦联合NS5A抑制剂失败的GT1患者SVR12率超过90%,但GT1a中基线NS5A耐药连锁数增加与SVR12率下降呈趋势。

研究设计与样本

  • 分析IIIb期随机实用临床试验中177例既往索磷布韦联合NS5A抑制剂失败的HCV GT1患者纵向样本。
  • 无肝硬化患者随机接受G/P 12周或16周;代偿期肝硬化患者随机接受G/P联合利巴韦林12周或G/P 16周。
  • 采用Primer-ID下一代测序以15%为阈值鉴定耐药连锁。

主要发现

  • 177例中169例(95.5%)为蛋白酶抑制剂初治;33例GT1b感染患者全部获得SVR12。
  • GT1a感染者基线NS5A耐药普遍(74.5%,105/141),NS3耐药少见;基线NS3耐药对G/P疗效无影响。
  • 基线NS5A耐药者SVR12率为89%,无NS5A耐药者为97%,差异无统计学意义。
  • 无、单、双连锁、三连锁NS5A替换者SVR12分别为34/35(97%)、53/57(93%)、35/40(88%)、5/8(63%)。
  • 13例病毒学失败者中,4例出现治疗 emergent NS3耐药,10例出现NS5A耐药。

关键数值与推荐

  • GT1a基线NS5A耐药患病率74.5%(105/141)。
  • 无NS5A基线替换者SVR12 34/35(97%),单连锁53/57(93%),双连锁35/40(88%),三连锁5/8(63%)。
  • 基线NS5A耐药者SVR12 89% vs 无耐药者97%,差异无统计学意义。

临床怎么用

  • G/P再治疗对既往索磷布韦联合NS5A抑制剂失败的GT1患者总体有效,GT1b均可获得SVR12。
  • GT1a患者基线NS5A耐药连锁数增加时SVR12率呈下降趋势,需关注多重连锁耐药者疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Retreatment with glecaprevir/pibrentasvir (G/P) resulted in a rate of sustained virologic response 12 weeks after treatment completion (SVR12) of >90% in HCV genotype 1 (GT1) patients who previously failed a regimen of sofosbuvir plus an NS5A inhibitor (NS5Ai). This study investigated the prevalence and impact of baseline NS3 and NS5A resistance-associated substitutions (RASs) on the efficacy of G/P in prior GT1 sofosbuvir+NS5Ai failures and the persistence of treatment-emergent RASs. METHODS: Longitudinal samples from 177 patients enrolled in a phase IIIb, randomized pragmatic clinical trial were analyzed. Patients without cirrhosis were randomized to 12 or 16 weeks of G/P, and patients with compensated cirrhosis were randomized to G/P and ribavirin for 12 weeks or G/P for 16 weeks. Linkage of RAS was identified using Primer-ID next-generation sequencing at a 15% cut-off. RESULTS: Of 177 patients, 169 (95.5%) were PI-naïve. All 33 GT1b-infected patients achieved SVR12. In GT1a-infected patients, baseline NS5A RASs were prevalent (74.5%, 105/141) but NS3 RASs were uncommon. Baseline NS3 RASs had no impact on G/P efficacy and patients with baseline NS5A RASs showed a numerically but not statistically significantly lower SVR12 rate compared to those without NS5A RASs (89% vs. 97%). SVR12 was achieved in 34 of 35 (97%) patients without NS5A baseline substitution, and 53 of 57 (93%), 35 of 40 (88%), 5 of 8 (63%) with single, double-linked, and triple-linked NS5A substitutions, respectively. Among 13 patients with virologic failure, 4 acquired treatment-emergent NS3 RASs and 10 acquired NS5A RASs. CONCLUSION: Baseline NS5A RASs were highly prevalent. The presence of an increasing number of linked NS5A RASs in GT1a showed a trend in decreasing SVR12 rates, although no specific NS5A RASs or their linkage pattern were associated with lower SVR12 rates. LAY SUMMARY: Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C infection, but treatment failure occurs in some patients. Retreatment of patients who previously failed a regimen consisting of sofosbuvir and an NS5A inhibitor with a regimen of glecaprevir and pibrentasvir (G/P) is >90% effective. Herein, we analyzed samples from these patients and showed that retreatment efficacy with G/P is lower in patients with double- or triple-linked NS5A resistance mutations than in patients with single or no NS5A resistance mutations. CLINICAL TRIAL NUMBER: NCT03092375.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang GP, Schnell GL, Kort JJ, et al. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol. 2021. PMID: 34023351. doi:10.1016/j.jhep.2021.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。